AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sol dude who wrote (1295)	4/4/1998 10:58:00 PM
From: Cacaito	Read Replies (1) of 2173

Sol dude, there is no way that insulin use by patients could be restricted in any way up or down if needed by the patients, just not morally correct, nobody will do that, the FDA will not allow that. One alternative is to design very expensive studies to correct for insulin variance with statistical tools (Multiple analysis of variance), this is what the company is trying to do in my view. Pramlintide is a drug that could take years (even decades)to learn the full benefits in terms of long term metabolic improvements and decreases in the complications of the disease. It will take many years to prove something like this and probably post marketing (my bias so far is that it will be approved in two or three years). Pramlintide could eventually showed decreases in chronic retinae, kidney and/or heart damage and these could possibly be the drug great value (long term). If they could find a quick two or three year model showing a benefit in chronic end organ damage the drug will be a sure hit both with the FDA and in the medical market. This is my hope, this is why I am following this company. Caveat, my money is not in this stock, just waiting for good news to get in.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next